Olema Pharmaceuticals (OLMA) Competitors $7.79 -0.49 (-5.92%) (As of 10:34 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OLMA vs. GLPG, XNCR, DVAX, NRIX, ARVN, HROW, KNSA, INDV, TVTX, and SYREShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Galapagos (GLPG), Xencor (XNCR), Dynavax Technologies (DVAX), Nurix Therapeutics (NRIX), Arvinas (ARVN), Harrow (HROW), Kiniksa Pharmaceuticals (KNSA), Indivior (INDV), Travere Therapeutics (TVTX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical preparations" industry. Olema Pharmaceuticals vs. Galapagos Xencor Dynavax Technologies Nurix Therapeutics Arvinas Harrow Kiniksa Pharmaceuticals Indivior Travere Therapeutics Spyre Therapeutics Galapagos (NASDAQ:GLPG) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings. Do analysts rate GLPG or OLMA? Galapagos presently has a consensus price target of $30.75, indicating a potential upside of 21.49%. Olema Pharmaceuticals has a consensus price target of $27.00, indicating a potential upside of 246.60%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of GLPG or OLMA? 32.5% of Galapagos shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is GLPG or OLMA more profitable? Galapagos' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Olema Pharmaceuticals N/A -53.56%-47.86% Which has more volatility & risk, GLPG or OLMA? Galapagos has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Which has stronger valuation & earnings, GLPG or OLMA? Galapagos has higher revenue and earnings than Olema Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$259.40M6.43$229.12MN/AN/AOlema PharmaceuticalsN/AN/A-$96.65M-$2.19-3.56 Does the media prefer GLPG or OLMA? In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Galapagos. MarketBeat recorded 11 mentions for Olema Pharmaceuticals and 9 mentions for Galapagos. Galapagos' average media sentiment score of 0.29 beat Olema Pharmaceuticals' score of 0.06 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor GLPG or OLMA? Galapagos received 436 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 66.67% of users gave Olema Pharmaceuticals an outperform vote while only 64.10% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.10% Underperform Votes26135.90% Olema PharmaceuticalsOutperform Votes3066.67% Underperform Votes1533.33% SummaryOlema Pharmaceuticals beats Galapagos on 8 of the 14 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$474.43M$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-3.7810.78126.3217.81Price / SalesN/A243.711,179.2574.56Price / CashN/A22.1633.8632.53Price / Book1.805.474.684.68Net Income-$96.65M$153.61M$119.54M$226.08M7 Day Performance-18.02%-2.00%-1.83%-1.04%1 Month Performance-31.40%-7.46%-3.60%1.04%1 Year Performance-41.69%31.82%31.91%26.28% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals1.7751 of 5 stars$7.79-5.9%$27.00+246.6%-48.1%$446.37MN/A-3.5680GLPGGalapagos1.2835 of 5 stars$25.31-1.3%$30.75+21.5%-31.4%$1.67B$259.40M0.001,123Analyst DowngradeShort Interest ↓News CoverageXNCRXencor3.5491 of 5 stars$23.69-0.1%$35.75+50.9%+19.3%$1.66B$168.34M-7.41280DVAXDynavax Technologies4.6909 of 5 stars$12.36+1.6%$22.00+78.0%-11.0%$1.62B$232.28M93.62408NRIXNurix Therapeutics2.7301 of 5 stars$22.54-0.4%$29.40+30.4%+247.8%$1.60B$76.99M0.00300ARVNArvinas3.0807 of 5 stars$23.05+1.6%$61.08+165.0%+4.2%$1.58B$78.50M0.00445Analyst ForecastShort Interest ↓News CoverageHROWHarrow3.7561 of 5 stars$42.29-0.4%$56.67+34.0%+348.6%$1.51B$130.19M-45.15182KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$20.73-2.3%$36.60+76.6%+33.9%$1.50B$270.26M0.00220INDVIndivior2.6488 of 5 stars$10.51-0.7%$16.00+52.2%-38.5%$1.45B$1.09B-264.431,164TVTXTravere Therapeutics3.0581 of 5 stars$18.36+2.8%$22.62+23.2%+210.6%$1.43B$145.24M0.00460SYRESpyre Therapeutics2.3417 of 5 stars$27.03-1.7%$48.57+79.7%N/A$1.39B$890,000.00-3.62100News Coverage Related Companies and Tools Related Companies GLPG Alternatives XNCR Alternatives DVAX Alternatives NRIX Alternatives ARVN Alternatives HROW Alternatives KNSA Alternatives INDV Alternatives TVTX Alternatives SYRE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OLMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts